Price Controls on Pharma
Total Page:16
File Type:pdf, Size:1020Kb
Load more
Recommended publications
-
Matthew Henry Kroenig, Georgetown University
“The Iran Deal and North Korea” Matthew Henry Kroenig, Georgetown University Friday, February 15, 2019, 6:30 pm - 8:00 pm Elliott School of International Affairs, Lindner Family Commons, The George Washington University 1957 E St. NW, Washington, DC 20052 ◊ Event Topics 1) Problems with the Joint Comprehensive Plan of Action (JCPOA) 2) Domestic and foreign backlash on the JCPOA 3) Similarities & differences of the two rogue nations (Iran & North Korea) 4) Possibility of setting a bad precedent with North Korea Speaker: Matthre Henry Kroenig, Georgetown University Matthew Kroenig is an Associate Professor in the Department of Government and the Edmund A. Walsh School of Foreign Service at Georgetown University and Deputy Director for Strategy in the Scowcroft Center for Strategy and Security at the Atlantic Council. His work has covered a wide range of topics in international relations and national security. Dr. Kroenig is the author or editor of six books, including The Logic of American Nuclear Strategy (Oxford University Press, forthcoming). His articles have appeared in many publications, including: American Political Science Review, Foreign Affairs, Foreign Policy, International Organization, The Wall Street Journal, and The Washington Post. He has served in several positions in the U.S. Department of Defense and the intelligence community and regularly consults with a wide range of U.S. government entities. He has previously worked as a research fellow at the Council on Foreign Relations, Harvard University, and Stanford University. Dr. Kroenig provides regular commentary for major media outlets, including PBS Newshour, Fareed Zakaria GPS, BBC, CNN, Fox News, NPR, and C- SPAN. -
20 13 Rep Or T
2013 REPORT More Than 240 Medicines in Development for Leukemia, Lymphoma and Other Blood Cancers Every 4 minutes a person is diagnosed with leukemia, Medicines in Development lymphoma or For Leading Blood Cancers myeloma; Accounting for Application Submitted 9% of all cancers Phase III diagnosed each year Phase II Biopharmaceutical research companies • 15 each for myeloproliferative neo- Phase I are developing 241 medicines for blood plasms, such as myelofibrosis, poly- cancers—leukemia, lymphoma and cythemia vera and essential throm- 97 98 myeloma. This report lists medicines in bocythemia; and for myelodysplastic human clinical trials or under review by syndromes, which are diseases affect- the U.S. Food and Drug Administration ing the blood and bone marrow. (FDA). These medicines in development offer The medicines in development include: hope for greater survival for the thou- sands of Americans who are affected by • 98 for lymphoma, including Hodgkin these cancers of the blood. and non-Hodgkin lymphoma, which 52 affect nearly 80,000 Americans each Definitions for the cancers listed in this year. report and other terms can be found on page 27. Links to sponsor company web • 97 for leukemia, including the four sites provide more information on the major types, which affect nearly potential products. 50,000 people in the United States 24 each year. For information on the value of medi- cines, an in-depth look at current in- • 52 for myeloma, a cancer of the novation and key medical breakthroughs plasma cells, which impacts more benefiting blood cancer patients, please than 22,000 people each year in the see Medicines in Development for Leu- United States. -
Scott D. Sagan
SCOTT D. SAGAN CURRICULUM VITAE February 2021 OFFICE ADDRESS: CISAC Encina Hall Room E217 616 Serra Street Stanford University Stanford, CA 94305-6165 (650) 725-2715 [email protected] CURRENT POSITIONS Caroline S.G. Munro Professor, Department of Political Science, Stanford University. Mimi and Peter Haas University Fellow in Undergraduate Education, Stanford University. Senior Fellow, Center for International Security and Cooperation, Freeman Spogli Institute for International Studies, Stanford University. EMPLOYMENT HISTORY Professor, Department of Political Science, Stanford University, 2001 – Present. Co-director, Center for International Security and Cooperation (CISAC), Stanford University, 1998-2011. Associate Professor, Department of Political Science, Stanford University, 1995-2001. Vice-Chairman, Department of Political Science, 1996-1999. Chairman, International Relations Program, Stanford University, 1995-1997. Assistant Professor, Department of Political Science, Stanford University, 1987-1995. Lecturer, Department of Government, Harvard University, 1986-1987. Consultant, Strategic Nuclear Policy Branch, Nuclear and Chemical Division, Organization of the Joint Chiefs of Staff, 1985-1986. 1 Research Fellow, The Center for International Affairs, Harvard University, 1985-1986. Council on Foreign Relations International Affairs Fellow, Special Assistant to the Director and Staff Officer, Nuclear/Chemical Division, Organization of the Joint Chiefs of Staff, 1984-1985. Postdoctoral Fellow, The Avoiding Nuclear War Project, Center for Science and International Affairs, Harvard University, 1983-84. EDUCATION Harvard University, Ph.D. (Political Science) 1983. Thesis: “Deterrence and Decision: An Historical Critique of Modern Deterrence Theory.” Winner of the American Political Science Association's 1983 Helen Dwight Reid Award for the best doctoral dissertation in international relations, law and politics. Oberlin College, B.A. with High Honors (Government) 1977. -
(2) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar Et Al
US 20090226500A1 (19) United States (2) Patent Application Publication (10) Pub. No.: US 2009/0226500 A1 Avelar et al. (43) Pub. Date: Sep. 10, 2009 (54) SUTURES AND ANTI-SCARRINGAGENTS Related U.S. Application Data (75) Inventors: Rui Avelar, Vancouver (CA); (60) Provisional application No. 60/763,945, filed on Jan. Arpita Maiti, Vancouver (CA); 31, 2006. Philip M. Toleikis, Vancouver (CA); Johanne Diane Cashman, Publication Classification Vancouver (CA); David M. (51) Int. Cl. Gravett, Mountain View, CA (US) A6.1 F 2/04 (2006.01) Correspondence Address: A61 K. 3 1/135 (2006.01) SEED INTELLECTUAL PROPERTY LAW A61R 31/553 (2006.01) GROUP PLLC A61 K 31/496 (2006.01) 701 FIFTHAVENUE, SUITE 5400 A61 K 31/4164 (2006.01) SEATTLE, WA 98104-7092 (US) A61R 31/395 (2006.01) A61 K 37/426 (2006.01) (73) Assignee: Angiotech Pharmaceuticals, Inc, (52) U.S. Cl. .................... 424/423: 514/649; 514/211.08; Vancouver (CA) 514/254.07: 514/399; 514/183; 514/370 (21) Appl. No.: 12/162,572 (57) ABSTRACT (22) PCT Filed: Jan. 31, 2007 Sutures are used in combination with anti-scarring agents to (86) PCT No.: PCT/US07/02714 inhibit fibrosis between the sutures and the host tissues into which the sutures are inserted. Compositions and methods are § 371 (c)(1), described for use in reducing excessive scarring, surgical (2), (4) Date: May 6, 2009 adhesion, and other disorders. Patent Application Publication Sep. 10, 2009 Sheet 1 of 29 US 2009/0226500 A1 Patent Application Publication Sep. 10, 2009 Sheet 2 of 29 US 2009/0226500 A1 ºs||eoL-AHLKquoqonpoudp-JNLWu018=ºolZ802-14Ke8 Patent Application Publication Sep. -
Novartis Venture Funds
N O V A R T I S VENTURE FUnDS activityreport 2010 2 l activity report 2010 Contents 04 Introduction 06 Investment Philosophy and Focus 08 Highlights 12 Our Funds 16 Geographic Presence 18 Pipelines of Portfolio Companies 22 Medical Device and Diagnostics 24 Private Equity Portfolio 32 Board of Directors 36 Fund Management 38 Contact Information 3 l activity report 2010 mission statement Investing in innovative life science companies for patient benefit creating attractive returns for entrepreneurs and investors 4 l activity report 2010 introduction francis waldvogel Letter from the Chairman of the Medical sciences have indeed never been as cre- Novartis Venture Fund ative, diversified, and dynamic as today, emerging Ranking systems have become fashionable: from from a real melting pot where physics, material sci- air transport to the life style of cities, from health ences, chemistry, biology, genetics, informatics and care systems to universities, we can today estab- robotics converge. Miniaturization and nanoscale lish the list of the best places to be in or the most developments also move into the field. We believe dedicated services to be bestowed with. Corporate therefore that this is a time for great opportuni- Venture Funds are also part of this trend, and to our ties to develop novel diagnostic tools, therapeu- great satisfaction, the Novartis Venture Funds (NVF) tic agents and medical devices for unmet patients’ have been ranked among the top performers in the needs, and that a diversified, multidisciplinary team life science field. is a must to develop these opportunities. Ranking systems, however, have their method- ological limitations and intellectual shortcomings. -
Prospectus for the Admission to Trading on the Regulated Market
Prospectus for the admission to trading on the regulated market operated by Euronext Amsterdam N.V. of 2,451,766 new ordinary bearer shares with no par value vested with full dividend rights as of 1 January 2018 from a capital increase against cash contributions as resolved by the management board with the consent of the supervisory board on 9 April 2019, registered in the Commercial Register on 10 April 2019 – each with a notional par value of EUR 1.00 per share – Vivoryon Therapeutics AG Halle (Saale) International Securities Identification Number (ISIN): DE0007921835 Ticker Symbol: VVY 26 June 2019 This document constitutes a prospectus for the purposes of the admission to trading of 2,451,766 new shares (the “Admission Shares”) on the regulated market operated by Euronext Amsterdam N.V. (the “Prospectus”). This Prospectus has been prepared in the English language in accordance with the Commission Regulation (EC) No 809/2004 of 29 April 2004 (the “Prospectus Regulation”) and conforms to the requirements of the German Securities Prospectus Act (Wertpapierprospektgesetz). Vivoryon Therapeutics AG is an SME in terms of art. 2 para. 1 f) in the Prospectus Directive (Prospektrichtlinie, “Prospectus Directive”) (No 2003/71/EC) and the level of disclosure of the Prospectus is proportionate to that type of issuer (Annex XXV of the Prospectus Regulation). This Prospectus has been approved by the German Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht) after a review for completeness of the Prospectus, including a review for coherence and comprehensibility of the presented information, according to Section 13 (1) of the German Securities Prospectus Act (Wertpapierprospektgesetz), and notified to the Netherlands Authority for the Financial Markets (Autoriteit Financiële Markten) in accordance with Section 18 (1) of the German Securities Prospectus Act (Wertpapierprospektgesetz) and the European passport mechanism set out in the Prospectus Directive. -
2020 Faculty & Guest Speakers
2020 FACULTY & GUEST SPEAKERS H.R. MCMASTER INtroductory Guest Speaker H. R. McMaster is the Fouad aNd Michelle Ajami SeNior Fellow at the Hoover INstitutioN, StaNford UNiversity. He is also the BerNard aNd SusaN Liautaud Fellow at the FreemaN Spogli INstitute aNd lecturer at StaNford UNiversity’s Graduate School of BusiNess. He was the 26th assistaNt to the presideNt for NatioNal Security Affairs. UpoN graduatioN from the UNited States Military Academy iN 1984, McMaster served as a commissioNed officer iN the UNited States Army for thirty-four years before retiriNg as a LieuteNaNt GeNeral iN JuNe 2018. McMaster holds a PhD iN military history from the UNiversity of North CaroliNa at Chapel Hill. He was aN assistaNt professor of history at the UNited States Military Academy from 1994 to 1996. He is author of BattlegrouNds: The Fight to DefeNd the Free World aNd the award-wiNNiNg DerelictioN of Duty. He was a coNtributiNg editor for Survival: Global Politics aNd Strategy from 2010 to 2017. His maNy essays, articles, aNd book reviews oN leadership, history, aNd the future of warfare have appeared iN The AtlaNtic, ForeigN Affairs, Survival, the Wall Street JourNal, aNd the New York Times. RAPHAEL COHEN SessioN 1: INtroductioN to NatioNal DefeNse Raphael "Rafi" CoheN is the associate director of the Strategy aNd DoctriNe Program iN Project AIR FORCE at RAND. He works oN a broad raNge of defeNse aNd foreigN policy issues, iNcludiNg defeNse strategy aNd force plaNNiNg, Middle East aNd EuropeaN security aNd civil-military relatioNs.CoheN previously held research fellowships at the BrookiNgs INstitutioN, the AmericaN ENterprise INstitute aNd the NatioNal DefeNse UNiversity’s CeNter for Complex OperatioNs. -
So I Realized That a Lot of Topics Have Very Similar Impacts (Soft Power
So I realized that a lot of topics have very similar impacts (soft power, relations, heg, econ, blah blah blah) and that a lot of cards from previous topic blockfiles could be useful in the future. So basically this file is a bunch of those previous cards organized into a file — the first part is the written up version, the second part is all the cards. Table of Contents (not exactly in order, just use command+F): Heg US Econ Climate change Democracy Allied prolif Cyber security Credibility/Allied commitment Multipolarity Soft Power/Diplomacy Multilateralism Deterrence Latin Relations China war impacts Chinese Aggression Russia impacts North Korea impacts Middle East stability etc Nuclear terror Drone strikes Interventions Donations to US campaigns Unions ISIL Trump has crazy fopo Al Qaeda Military Readiness LNG impacts Free Trade Federalism Oil Spills Appeasement/weakness thesis Resource wars Microfinance Renewables transition Social movements Offshore Balancing Written blocks AT: Hegemony GOOD: qa China nuclear war: 1. International affairs professor Robert Gilpin confirms in 2013 that if US hegemony declines and China becomes a challenger, a war between the US and China is practically guaranteed, as no dominant state in history has ever relinquished its position without a fight and no rising power has ever established itself as dominant without winning a great power war. Professor of political science Caitlin Talmadge furthers in 2016 that because China and the US would be unable to distinguish between conventional strikes and attempts to destroy the other’s nuclear capability, a US China war would have a high chance of going nuclear. -
The History of Proliferation Optimism: Does It Have a Future?
This article was downloaded by: [Charles University in Prague] On: 28 July 2015, At: 05:58 Publisher: Routledge Informa Ltd Registered in England and Wales Registered Number: 1072954 Registered office: 5 Howick Place, London, SW1P 1WG Journal of Strategic Studies Publication details, including instructions for authors and subscription information: http://www.tandfonline.com/loi/fjss20 The History of Proliferation Optimism: Does It Have a Future? Matthew Kroenigab a Associate Professor and International Relations Field Chair, Department of Government Georgetown University, Washington DC, USA b Nonresident Senior Fellow, Brent Scowcroft Center on International Security, The Atlantic Council Published online: 24 Apr 2014. Click for updates To cite this article: Matthew Kroenig (2015) The History of Proliferation Optimism: Does It Have a Future?, Journal of Strategic Studies, 38:1-2, 98-125, DOI: 10.1080/01402390.2014.893508 To link to this article: http://dx.doi.org/10.1080/01402390.2014.893508 PLEASE SCROLL DOWN FOR ARTICLE Taylor & Francis makes every effort to ensure the accuracy of all the information (the “Content”) contained in the publications on our platform. However, Taylor & Francis, our agents, and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Taylor and Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to or arising out of the use of the Content. -
Lenalidomide for Newly Diagnosed MM and the Incidence of Second Primary Cancer
Key ASH Presentations Issue 7, 2012 Lenalidomide for Newly Diagnosed MM and the Incidence of Second Primary Cancer For more visit ResearchToPractice.com/5MJCASH2012 CME INFORMATION OVERVIEW OF ACTIVITY The annual American Society of Hematology (ASH) meeting is unmatched in its importance with regard to advancements in hematologic cancer and related disorders. It is targeted by many members of the clinical research community as the optimal forum in which to unveil new clinical data. This creates an environment each year in which published results and new information lead to the emergence of many new therapeutic agents and changes in the indications for existing treatments across virtually all malignant and benign hematologic disorders. As online access to posters and plenary presentations is not currently available, a need exists for additional resources to distill the information presented at the ASH annual meeting for those clinicians unable to attend but desiring to remain up to date on the new data released there. To bridge the gap between research and patient care, this CME activity will deliver a serial review of the most important emerging data sets from the latest ASH meeting, including expert perspectives on how these new evidence-based concepts can be applied to routine clinical care. This activity will assist medical oncologists, hematologists and hematology-oncology fellows in the formulation of optimal clinical management strategies and the timely application of new research findings to best-practice patient care. LEARNING OBJECTIVES • Integrate emerging research information on the use of proteasome inhibitors and immunomodulatory agents to individualize induction treatment recommendations and maintenance therapeutic approaches for elderly patients with multiple myeloma. -
DIA 2012 Collaborate to Innovate
GLOBAL ggff forumJUNE 2012 VOL 4 • ISSUE 3 INFORM ADVISE REACH EDUCATE DON’T MISS!! DIA 2012 CollaboRatE to INNOVatE 48TH ANNUAL MEETING JUNE 24 – 28 PHiladELPHIA Cover, TOC and Intro articles.indd 1 6/5/12 2:57 PM Cover, TOC and Intro articles.indd 2 6/5/12 2:57 PM ggff CONTCONTEENTSNTS INFORM ADVISE REACH EDUCATE Devised to Time What we are Keeps you educate and management, doing around abreast of update you on skill the globe and all association, advances in a development, how advances membership, specific area of technology, in each region regulatory, research, drugs, software topics can have a and diagnostics or and more are worldwide legislative 3 devices. 14 examined. 30 impact. 48 news. 102 In Every Issue Open Forum 6 Andrzej Czarnecki President’s Message 8 Yves Juillet Executive Director’s Message 10 Paul Pomerantz Association News Award Winners at DIA 2012 110 Devices & Diagnostics Newest SIAC 117 Guide to New & Improved Website 119 DIA Elects 2012 Board of Directors 122 Patient Perspective From Naiveté to Understanding 126 Members on the Move 129 Marketplace 130 Cover, TOC and Intro articles.indd 3 6/5/12 2:58 PM gf GLOBAL FORUM The Global Forum (ISSN: 1944-1991) is a publication of the Drug Information Association. Editorial Office: Drug Information Association (DIA), 800 Enterprise Road, Suite 200, Horsham, PA 19044-3595, USA; phone - 215.442.6100; fax: 215.442.6199. PUBLISHING Copyright © 2012, Drug Information Association. INFORMATION The Global Forum (ISSN: 1944-1991) is published six times a year, in February, April, June, August, October, and December. -
Study in Support of Impact Assessment Work on Blue Biotechnology
Study in support of Impact Assessment work on Blue Biotechnology Final Report FWC MARE/2012/06 – SC C1/2013/03 Client: DG Maritime Affairs and Fisheries London/Berlin/Brussels/Rotterdam, 8 April 2014 Client: DG Maritime Affairs and Fisheries London/Berlin/Brussels/Rotterdam, 8 April 2014 Study in support of Impact Assessment work on Blue Biotechnology About Ecorys and Consortium Partners Consortium Lead Partner ECORYS Nederland BV P.O. Box 4175 3006 AD Rotterdam The Netherlands T +31 (0)10 453 88 00 F +31 (0)10 453 07 68 E [email protected] Registration no. 24316726 www.ecorys.com Study in support of Impact Assessment work on Blue Biotechnology Table of Content Executive Summary i 1 Introduction and policy context 1 1.1 Background and Objectives 1 1.2 Definition of Blue Biotechnology sector 1 1.2.1 Definition of marine biotechnology 1 1.2.2 Defining the Blue Biotechnology sector 2 1.3 Policy context 3 2 State of play: Importance of Blue Biotechnology 5 2.1 Value chain of Blue Biotechnology 5 2.1.1 Discovery, bioprospecting and R&D- the blue components of the value chain 6 2.1.2 Closing the marine biotechnology loop: the ‘blue’ application of marine biotechnology' 7 2.2 Overall size and structure of the Blue Biotechnology sector 7 2.2.1 Size 7 2.2.2 Structure 8 2.3 Global settings of Blue Biotechnology 9 2.4 Blue Biotechnology within the wider biotechnology landscape 10 2.5 Conclusions 10 3 EU-level problem analysis 13 3.1 Sector review 13 3.1.1 Overview of sub-sectors 13 3.1.2 Potential product areas in research and development